The announcement of a public offering typically leads to short-term negative pressure on a company's stock price due to the dilution of existing shares. However, the capital raised can be beneficial for the company's long-term growth and development. The impact score is -1, reflecting the potential short-term negative sentiment among investors. The relevance is set at 100 as the news is directly about Immatics. The importance is 75, considering that the offering is significant but not uncommon for biotech companies seeking to raise capital. The confidence level is 90, acknowledging the general market reaction to such news while allowing for variations based on market conditions and investor perceptions.